Every 8-K that 908 Devices Inc. (MASS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MASS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MASS filings page.
908 Devices Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $16.1 million, up 23% year-over-year, driven by VipIR product demand and initial NIRLab contribution. The installed base grew 23% to 4,101 devices, including 198 devices placed in the quarter, and recurring revenue represented 31% of total revenue.
GAAP gross profit was $8.3 million with a 52% gross margin, while adjusted gross margin improved to 57%. Operating expenses were $21.2 million, including a sizeable noncash charge from the change in fair value of contingent consideration, leading to a net loss from continuing operations of $11.9 million. Adjusted EBITDA loss narrowed to $1.9 million, more than half the prior-year level.
The company held $101.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, with no debt, after using $13.5 million for the NIRLAB SA acquisition and receiving $3.5 million from an escrow release. Full-year 2026 revenue guidance was raised at the low end to $68.0–$70.0 million, representing 21%–25% growth versus 2025.
908 Devices Inc. issued 3,213,583 shares of common stock to satisfy the earnout consideration tied to its acquisition of RedWave Technology. These shares fulfill the company’s obligations under the April 29, 2024 Equity Purchase Agreement with CAM3 HoldCo, LLC and related sellers. The earnout was based on revenue from certain RedWave products and services over the period from May 1, 2024 through April 30, 2026, measured against a $37 million revenue threshold set in the agreement. With this issuance, the company states that its earnout obligations under the purchase agreement are now fully satisfied.
908 Devices Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the April 16, 2026 record date, 37,446,534 common shares were outstanding and entitled to vote, and 28,653,832 shares were present in person or by proxy, representing 76.52% of eligible shares and constituting a quorum.
Stockholders elected three Class III directors—Keith L. Crandell, Christopher Brown, Ph.D., and E. Kevin Hrusovsky—to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
In an advisory vote, stockholders approved the compensation of the company’s named executive officers. In a separate advisory vote on the frequency of future say-on-pay votes, stockholders favored holding the vote every one year. The board determined that future advisory votes on executive compensation will be held annually until the next required frequency vote.
908 Devices Inc. completed the acquisition of Swiss-based NIRLAB, a near‑infrared spectroscopy company, for a preliminary $15 million, split between $13 million in cash and 293,368 shares of common stock, plus up to $8 million in stock earn‑outs tied to revenue milestones through December 31, 2027.
Q1 2026 revenue was $13.4 million, up 14% year over year, with growth in both mass spectrometry and FTIR products. GAAP gross margin improved to 51%, and adjusted gross margin to 57%, while adjusted EBITDA loss narrowed to $2.5 million. The company reported a continuing-operations net loss of about $12.0 million, supported by $111.7 million of cash, cash equivalents and marketable securities and no debt as of March 31, 2026.
The installed base grew 23% to 3,903 devices, with recurring revenue at 30% of total. Management raised full‑year 2026 revenue guidance to a range of $67.0–$70.0 million, representing 19%–25% growth versus 2025.
908 Devices Inc. reported fourth-quarter and full-year 2025 results and provided a 2026 revenue outlook. Q4 2025 revenue was $17.4 million, up 21% year over year, and net income from continuing operations reached $4.4 million, with positive Adjusted EBITDA of $0.7 million.
For 2025, revenue from continuing operations was $56.2 million, an 18% increase, while net loss from continuing operations narrowed to $33.3 million. Net income attributable to common stockholders was $19.5 million, helped by discontinued operations, and cash, cash equivalents and marketable securities totaled $113.0 million with no debt.
The company expects 2026 revenue between $64.5 million and $67.5 million, representing 15% to 20% growth over 2025 revenue from continuing operations.
908 Devices Inc. furnished a Form 8-K to report that it has announced preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. The company issued a press release on January 20, 2026 describing these preliminary results, which is included as Exhibit 99.1.
The information about results of operations and financial condition is being furnished under Item 2.02 of the Form 8-K and is not considered filed for purposes of certain liability provisions of the federal securities laws, unless specifically incorporated by reference in other filings.
908 Devices Inc. (MASS) furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is attached as Exhibit 99.1 to a Form 8-K dated November 10, 2025.
The information under Item 2.02 is being furnished, not filed, under the Exchange Act. MASS’s common stock trades on The NASDAQ Global Market.